Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 190

Sort by

Sort Order Select

Journal Articles

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Xiaoli Wang, Cing Siang Hu, Xiaoping Su, Raajit Rampal, Noushin Farnoud, Erin McGovern, Andrew Davis, Sophia Jiang, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman

Blood (2025) 146 (Supplement 1): 359.

https://doi.org/10.1182/blood-2025-359

Published: 2025

Journal Articles

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

John Mascarenhas, Andrew Kuykendall, Terrence Bradley, Bart Scott, Habte Yimer, Yiqun Yang, Fei Huang, Ying Wan, Shyamala Navada, Judy Ho, Tymara Berry, Salman Otoukesh

Blood (2025) 146 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2025-2052

Published: 2025

Journal Articles

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2025-2051

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Long term outcomes of ET and PV patients after clinical trial treatment with interferon alfa

Megan Metzger, Heidi Kosiorek, Ashley Yu, Veer Shah, Nooshin Beygui, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 7345.

https://doi.org/10.1182/blood-2025-7345

Published: 2025

Journal Articles

Leveraging real-world workshop insights for improving education design: Patient-centered care of myelofibrosis with JAK inhibitors

Kristen Rosenthal, John Mascarenhas, Raajit Rampal, Shara Pantry, Carley Yawn, Sarah Nisly, Jason Everly, Timothy Quill, Kevin Obholz

Blood (2025) 146 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2025-2871

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 483.

https://doi.org/10.1182/blood-2025-483

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis

Richard Sheppard, Noa Rippel, Hulya Kocyigit, Erin Moshier, Kyle Wiatrowski, John Levine, John Mascarenhas, Ronald Hoffman, Alla Keyzner

Blood (2025) 146 (Supplement 1): 2530.

https://doi.org/10.1182/blood-2025-2530

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib, Claire Harrison, John Mascarenhas, Erin Crowgey, Betty Lamothe, Chenwei Tian, Evan Braunstein, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 71.

https://doi.org/10.1182/blood-2025-71

Published: 2025

Journal Articles

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

John Crispino, Jeremy Wen, Anitria Cotton, Rashid Mehmood, Amber Broadhurst, Trent Hall, Bridget Marcellino, John Mascarenhas, Ronald Hoffman, Laura Janke, Sandeep Gurbuxani, Gerard McGeehan

Blood (2025) 146 (Supplement 1): 67.

https://doi.org/10.1182/blood-2025-67

Published: 2025

Journal Articles

Characterization of disease presentation and clinical outcomes of chronic myelomonocytic leukemia and myelofibrosis with monocytosis

Patrick Crorkin, John Mascarenhas, Douglas Tremblay

Blood (2025) 146 (Supplement 1): 7348.

https://doi.org/10.1182/blood-2025-7348

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Graham Wehmeyer, Ryan Jin, Vesna Najfeld, Megan Metzger, Theodora Anagnostou, Patricia Arboleda Ezcurra, Janice Gabrilove, Marina Kremyanskaya, John Mascarenhas, Christian Salib, Ilan Shapira, Jonah Shulman, Suchitra Sundaram, Douglas Tremblay, Adam Kittai

Blood (2025) 146 (Supplement 1): 5674.

https://doi.org/10.1182/blood-2025-5674

Published: 2025

Journal Articles

Real-world risk of vascular events in patients with myeloproliferative neoplasms compared to the danish general population

Dustin Andersen Patel, Volkert Siersma, Mark Meisner Jensen, John Mascarenhas, Kirsten Gronbaek, Anne Stidsholt Roug, Tarec Christoffer El-Galaly, Christen Lykkegaard Andersen

Blood (2025) 146 (Supplement 1): 2015.

https://doi.org/10.1182/blood-2025-2015

Published: 2025

Journal Articles

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

John Mascarenhas, Justin Johnson, Heidi Kosiorek, Megan Metzger, Tiziano Barbui, Josef Prchal, Alessandro Rambaldi, Abdulraheem Yacoub, Ashley Yu, Ruben Mesa, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, Mohamed Salama

Blood (2025) 146 (Supplement 1): 5590.

https://doi.org/10.1182/blood-2025-5590

Published: 2025

Journal Articles

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

John Mascarenhas, Claire Harrison, Alessandro Lucchesi, Angela Fleischman, Rami Komrokji, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Yiqun Yang, Libo Sun, Ying Wan, Michelle Mudge-Riley, Tymara Berry, Faye Feller, Fei Huang, Prithviraj Bose

Blood (2025) 146 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2025-5585

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Long term outcomes of ET and PV patients after clinical trial treatment with interferon alfa

Leveraging real-world workshop insights for improving education design: Patient-centered care of myelofibrosis with JAK inhibitors

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Characterization of disease presentation and clinical outcomes of chronic myelomonocytic leukemia and myelofibrosis with monocytosis

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Real-world risk of vascular events in patients with myeloproliferative neoplasms compared to the danish general population

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only